Denzinger Stefan, Otto Wolfgang, Burger Maximilian, Hammerschmied Christine, Junker Kerstin, Hartmann Arndt, Wieland Wolf F, Walter Bernhard
Department of Urology, University of Regensburg, Regensburg, Germany.
World J Surg Oncol. 2007 Feb 5;5:16. doi: 10.1186/1477-7819-5-16.
Sporadic renal cell carcinoma (RCC) is rare in young adults. In the present retrospective study we reviewed clinicopathological features and disease specific survival rates in young patients (<= 45 years) with RCC and compared them to old patients (>= 75 years) with RCC.
Between 1992 and 2005 a total of 1042 patients were treated for RCC at our institution. We found 70 patients 45 years or younger (YP) and 150 patients 75 years or older (OP) at time of diagnosis. There were no differences in therapeutical approaches between both groups. Clinical and biologic parameters at diagnosis were compared and subjected to uni- and multivariate analysis to study cancer specific survival and progression rate. Mean postoperative follow-up in both groups was 50.1 months.
Mean age was 39 years in YP and 80 years in OP, respectively. YP demonstrated significantly lower stage (pT1-pT2 N0 M0, p = 0.03), lower tumor grade (p = 0.01) and higher male-to-female ratio (p < 0.001). The rate of lymph node metastases or distant metastatic disease at presentation did not differ significantly between both groups. In multivariate analysis young age was independently associated with a higher 5-year cancer specific survival (95.2% vs. 72.3%, p = 0.009) and a lower 5-year progression rate (11.3% vs. 42.5%, p = 0.002).
Sporadic RCC in young patients have lower tumor stages and grades and a better outcome compared to elderly. Age <= 45 years was an independent prognostic factor for survival and progression.
散发性肾细胞癌(RCC)在年轻成年人中较为罕见。在本回顾性研究中,我们回顾了年轻(≤45岁)RCC患者的临床病理特征和疾病特异性生存率,并将其与老年(≥75岁)RCC患者进行比较。
1992年至2005年间,共有1042例患者在我们机构接受了RCC治疗。我们发现70例诊断时年龄为45岁及以下(年轻组)和150例诊断时年龄为75岁及以上(老年组)的患者。两组之间的治疗方法没有差异。比较诊断时的临床和生物学参数,并进行单因素和多因素分析,以研究癌症特异性生存率和进展率。两组的平均术后随访时间为50.1个月。
年轻组的平均年龄为39岁,老年组为80岁。年轻组的分期(pT1 - pT2 N0 M0,p = 0.03)、肿瘤分级(p = 0.01)明显更低,男女比例更高(p < 0.001)。两组初诊时淋巴结转移或远处转移疾病的发生率没有显著差异。在多因素分析中,年轻年龄独立与更高的5年癌症特异性生存率(95.2%对72.3%,p = 0.009)和更低的5年进展率(11.3%对42.5%,p = 0.002)相关。
与老年患者相比,年轻患者的散发性RCC肿瘤分期和分级更低,预后更好。年龄≤45岁是生存和进展的独立预后因素。